2008, Número 2
Siguiente >>
Gac Med Mex 2008; 144 (2)
Estudio de asociación y metaanálisis del gen de la apolipoproteína E y esquizofrenia
Tovilla-Zárate C, Camarena B, Apiquian R, Nicolini H
Idioma: Español
Referencias bibliográficas: 37
Paginas: 79-83
Archivo PDF: 101.02 Kb.
RESUMEN
Antecedentes: La esquizofrenia es una enfermedad mental cuyas causas etiológicas son desconocidas. Los estudios de epidemiología genética, de asociación y de ligamiento, han sugerido la presencia de factores genéticos involucrados en el desarrollo de la esquizofrenia. Existen numerosos estudios dirigidos a comprender la participación del gen de la apolipoproteína E (ApoE) en la esquizofrenia, sin embargo, los resultados son controversiales por la falta de replicación de los hallazgos.
Objetivo: Para conocer el efecto del alelo ε4 de ApoE en esquizofrenia, se analizó la frecuencia de genotipos y alelos de ApoE en pacientes de origen mexicano.
Resultados y conclusiones: No observamos diferencias estadísticamente significativas en los pacientes con esquizofrenia comparados con el grupo control en las frecuencias por alelos (χ
2=0.94, gl=2, p=0.62) ni por genotipos (χ
2=1.02, gl=2, p=0.59). Finalmente, el metaanálisis de 19 estudios de asociación, incluyendo el presente estudio, mostró que el alelo de riesgo ε4 de ApoE no está asociado con el desarrollo de la esquizofrenia (OR=1.04, IC 95%=0.90-1.21, p=0.184), sin la presencia de heterogeneidad (χ
2=18.8, gl=18, p=0.4).
REFERENCIAS (EN ESTE ARTÍCULO)
Jablensky A. The concept of schizophrenia: pro et contra. Epidemiol Psichiatr Soc 1999;8:242-247.
Gottesman II, Bertelsen A. Confirming unexpressed genotypes for schizophrenia. Risks in the offspring of Fischer’s Danish identical and fraternal discordant twins. Arch Gen Psychiatry 1989;46:867-872.
Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, et al. Apolipoprotein E polymorphism is associated with age of onset in schizophrenia. J Hum Genet 2004;49:355-359.
Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E (LDL) receptors in the brain. J Biol Chem 1987;262:14352-14360.
Siest G, Bertrand P, Herbeth B, Vincent-Viry M, Schiele F, Sass C, et al. Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin Chem Lab Med 2000;38:841-852.
Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
Frisoni GB, Calabresi L, Geroldi C, Bianchetti A, D’Acquarica AL, Govoni S, et al. Apolipoprotein E epsilon 4 allele in Alzheimer’s disease and vascular dementia. Dementia 1994;5:240-242.
Benjamin R, Leake A, Edwardson JA, McKeith IG, Ince PG, Perry RH, et al. Apolipoprotein E genes in Lewy body and Parkinson’s disease. Lancet 1994;343:1565.
Royston MC, Mann D, Pickering-Brown S, Owen F, Perry R, Ragbavan R, et al. ApoE2 allele, Down’s syndrome, and dementia. Ann N Y Acad Sci 1996;777:255-259.
Amouyel P, Vidal O, Launay JM, Laplanche JL. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet 1994;344:1315-1318.
Farrer LA, Abraham CR, Volicer L, Foley EJ, Kowall NW, McKee AC, et al. Allele epsilon 4 of apolipoprotein E shows a dose effect on age at onset of Pick disease. Exp Neurol 1995;136:162-170.
Harrington CR, Roth M, Xuereb JH, McKenna PJ, Wischik CM. Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. Neurosci Lett 1995;202:101-104.
Chen JY, Hong CJ, Chiu HJ, Lin CY, Bai YM, Song HL, et al. Apolipoprotein E genotype and schizophrenia. Neuropsychobiology 1999;39:141-143.
Lan TH, Hong CJ, Chen JY and Sim CB. Apolipoprotein E-epsilon 4 frequency in patients with schizophrenia. Biol Psychiatry 1997;42:225-227.
Schurhoff F, Krebs MO, Szoke A, Loze JY, Goldberger C, Quignon V, et al. Apolipoprotein E in schizophrenia: a French association study and metaanalysis. Am J Med Genet B Neuropsychiatr Genet 2003;119:18-23.
Arnold SE, Joo E, Martinoli MG, Roy N, Trojanowski JQ, Gur RE, et al. Apolipoprotein E genotype in schizophrenia: frequency, age of onset, and neuropathologic features. Neuroreport 1997;8:1523-1526.
Martorell L, Virgos C, Valero J, Coll G, Figuera L, Joven J, et al. Schizophrenic women with the APOE epsilon 4 allele have a worse prognosis than those without it. Mol Psychiatry 2001;6:307-310.
Saiz PA, Morales B, MP GP, Álvarez V, Coto E, Fernández JM, et al. Apolipoprotein E genotype and schizophrenia: further negative evidence. Acta Psychiatr Scand 2002;105:71-75.
Sorbi S, Nacmias B, Tedde A, Latorraca S, Forleo P, Guarnieri BM, et al. No implication of apolipoprotein E polymorphism in Italian schizophrenic patients. Neurosci Lett 1998;244:118-120.
Zhu S, Nothen MM, Uhlhaas S, Rietschel M, Korner J, Lanczik M, et al. Apolipoprotein E genotype distribution in schizophrenia. Psychiatr Genet 1996;6:75-79.
Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991;19:5444.
Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by onestage PCR. Lancet 1991;337:1158-1159.
Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am J Psychiatry 2003;160:469-476.
Leandro G: Meta-analysis in medical research: the handbook for the understanding and practice of meta-analysis, vol. 1. Massachusetts, USA: Blackwell Publishing Ltd.; 2006.
Liu W, Breen G, Zhang J, Li S, Gu N, Feng G, et al. Association of APOE gene with schizophrenia in Chinese: a possible risk factor in times of malnutrition. Schizophr Res 2003;62:225-230.
Pickar D, Malhotra AK, Rooney W, Breier A, Goldman D. Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet 1997;350:930-931.
Durany N, Riederer P, Cruz-Sánchez FF. Apolipoprotein E genotype in Spanish schizophrenic patients. Psychiatr Genet 2000;10:73-77.
Cruz-Fuentes CS, González-Sobrino BZ, Gómez-Sánchez A, Martínez-Rueda H, Chávez-Eakle RA, Serrano-Sánchez C. Distribution of apolipoprotein E alleles in coras and huicholes from Nayarit and Nahuas and Mestizos from Veracruz, Mexico. Hum Biol 2005;77:867-872.
Igata-Yi R, Igata T, Ishizuka K, Kimura T, Sakamoto S, Katsuragi S, et al. Apolipoprotein E genotype and psychosis. Biol Psychiatry 1997;41:906-908.
Joober R, Rouleau G, Fon E, Lal S, Palmour R, Bloom D, et al. Apolipoprotein E genotype in schizophrenia. Am J Med Genet 1996;67:235.
Kimura T, Yokota S, Shono M, Igata-Yi R, Takamatsu J, Miyakawa T. Apolipoprotein E epsilon 4 allele and schizophrenia. Neuroreport 1997;8:i-ii.
Kimura T, Shono M, Yokota S, Igata-Yi R, Takamatsu J, Miyakawa T. Apolipoprotein E epsilon 3 allele is not a risk factor of schizophrenia: a study of 314 Japanese patients. Neuropsychobiology 2000;42:66-68.
Fernández T, Yan WL, Hamburger S, Rapoport JL, Saunders AM, Schapiro M, et al. Apolipoprotein E alleles in childhood-onset schizophrenia. Am J Med Genet 1999;88:211-213.
Moberg PJ, Arnold SE, Roalf DR, Balderston CC, Abbazia J, Kohler CG, et al. Apolipoprotein E genotype and odor identification in schizophrenia. J Neuropsychiatry Clin Neurosci 2006;18:231-233.
Thibaut F, Van Der Elst A, Campion D, Martin C, Coron B, Dollfus S, et al. Apolipoprotein E-varepsilon 4 frequency in deficit schizophrenia. Eur Psychiatry 1999;14:148-151.
Town T, Fallin D, Crawford F, Walsh S, Solomon R, Mullan M. Lack of association between the apolipoprotein E epsilon 4 allele (APOE epsilon 4) and chronic schizophrenia. Am J Med Genet 1997;74:451-452.
Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csazar A, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991;49:338-349.